Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab, Acalabrutinib, and Obinutuzumab in Untreated CLL/SLL
NCT05943496Phase 1Recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tafasitamab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Incidence of dose limiting toxicities and Measurable Residual Disease Negativity up to 2 years. Started Oct 2023; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05943496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943496.